Inhibitor screening of Spike variants reveals the heterogeneity of neutralizing antibodies to COVID-19 infection and vaccination

Xiaomei Zhang^{1,8}, Mei Zheng^{2,3,5,8}, Te Liang^{1,8}, Haijian Zhou^{4,5,8}, Hongye Wang¹, Jiahui Zhang¹, Jing Ren¹, Huoying Peng¹, Siping Li¹, Haodong Bian¹, Chundi Wei¹, Shangqi Yin^{2,3,5}, Chaonan He^{2,3,5}, Ying Han^{2,3,5}, Minghui Li^{4,5}, Xuexin Hou^{4,5}, Jie Zhang⁶, Liangzhi Xie⁶, Jing Lv⁷, Biao Kan^{4,5,9}, Yajie Wang^{2,3,5,9}, Xiaobo Yu^{1,9}

Affiliations

¹ State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences-Beijing (PHOENIX Center), Beijing Institute of Lifeomics, Beijing, 102206, China.

² Department of Clinical Laboratory, Beijing Ditan Hospital, Capital Medical University, Beijing, China.

³ Department of Research Ward, Beijing Ditan Hospital, Capital Medical University, Beijing, China.

⁴ State Key Laboratory of Infectious Disease Prevention and Control, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China

⁵ Joint Laboratory for Pathogen Identification of ICDC and Ditan Hospital, Beijing, 102206, China

⁶ Beijing Key Laboratory of Monoclonal Antibody Research and Development,
Sino Biological, Inc., Beijing, 100176, China

⁷ Gobond Testing Technology (Beijing) Co., Ltd., Beijing, 102629, China.

26

⁸ These authors contributed equally to this work.

⁹ Correspondence: xiaobo.yu@hotmail.com (X. Y.), wangyajie@ccmu.edu.cn
(Y. W.), kanbiao@icdc.cn (B. K.)

30

31 **Highlights**

- 32 ● Developed a high throughput assay to screen the neutralizing effect of
33 antibodies across multiple SARS-CoV-2 Spike variants simultaneously.
- 34 ● Characterized the heterogeneity of neutralizing antibodies produced in
35 response to COVID-19 infection and vaccination.
- 36 ● Demonstrated the capacity of Spike variants neutralization is associated
37 with the diversity of anti-Spike antibodies.

38

39 **Abstract**

40 Mutations of the coronavirus responsible for coronavirus disease 2019
41 (COVID-19) could impede drug development and reduce the efficacy of
42 COVID-19 vaccines. Here, we developed a multiplexed Spike-ACE2 Inhibitor
43 Screening (mSAIS) assay that can measure the neutralizing effect of
44 antibodies across numerous variants of the coronavirus's Spike (S) protein

45 simultaneously. By screening purified antibodies and serum from convalescent
46 COVID-19 patients and vaccinees against 72 S variants with the mSAIS assay,
47 we identified new S mutations that are sensitive and resistant to neutralization.
48 Serum from both infected and vaccinated groups with a high titer of
49 neutralizing antibodies (NAbs) displayed a broader capacity to neutralize S
50 variants than serum with low titer NAbs. These data were validated using
51 serum from a large vaccinated cohort (n=104) with a tiled S peptide microarray.
52 In addition, similar results were obtained using a SARS-CoV-2 pseudovirus
53 neutralization assay specific for wild-type S and four prevalent S variants
54 (D614G, B.1.1.7, B.1.351, P.1), thus demonstrating that high antibody diversity
55 is associated with high NAb titers. Our results demonstrate the utility of the
56 mSAIS platform in screening NAbs. Moreover, we show that heterogeneous
57 antibody populations provide a more protective effect against S variants, which
58 may help direct COVID-19 vaccine and drug development.

59

60 **Keywords**

61 SARS-CoV-2, COVID-19, microarray, neutralizing antibody, mutation, Spike

62

63 **Introduction**

64 Coronavirus disease 2019 (COVID-19) is caused by the severe respiratory
65 coronavirus 2 (SARS-CoV-2). As of May 2021, SARS-CoV-2 had infected 162
66 million people and caused over three million deaths worldwide (Dong et al.,

2020). A key step in infection is viral entry, which is facilitated by the interaction between the SARS-CoV-2 Spike (S) protein via its receptor binding domain (RBD) (319 – 541 aa) with the human Angiotensin-Converting Enzyme 2 (ACE2) receptor. Thus, this interaction is a major focus in drug and vaccine development efforts (Burki, 2021; Dai and Gao, 2021). For example, the current COVID-19 vaccines approved by the U.S. Food and Drug Administration (FDA) stimulate the immune response to generate antibodies capable of neutralizing the Spike-ACE2 interaction. Unfortunately, SARS-CoV-2 is mutating, with new variants emerging nearly every week that could impede drug development and reduce the efficacy of COVID-19 vaccines (Dai and Gao, 2021; Kemp et al., 2021).

Mutations in the S protein are of particular concern since they could enable SARS-CoV-2 to evade defense mechanisms that are elicited by COVID-19 vaccines and therapeutic antibodies (Aschwanden, 2021; Del Rio and Malani, 2021). For example, the D614G variant, which was first identified in July 2020, has a faster infection rate and higher viral load in the upper respiratory tract than the wild-type “Wuhan-Hu-1” strain (Hou et al., 2020b; Korber et al., 2020). It has since become one the most prevalent strains. The B.1.1.7 variant (D614G, N501Y) is more infectious and may lead to increased mortality compared to the parental strain (Davies et al., 2021; Galloway et al., 2021). The B.1.351 and P.1 variants contain three RBD mutations at E484K, N501Y, and K417N or K417T, respectively. These mutations have shown

89 resistance to neutralizing antibodies (NAbs) produced by convalescent
 90 COVID-19 patients and vaccinees that inhibit the wild-type Spike-ACE2
 91 interaction (Garcia-Beltran et al., 2021; Liu et al., 2021; Madhi et al., 2021;
 92 Wang et al., 2021a; Wang et al., 2021b; Wibmer et al., 2021). The vaccinees in
 93 these studies received the most popular vaccines worldwide, including
 94 mRNA-based COVID-19 vaccines (Moderna and Pfizer BioNTech) and a
 95 replication-deficient chimpanzee adenoviral vector COVID-19 vaccine
 96 (AstraZeneca). Similar results were obtained when testing a B.1.1.7 variant
 97 with an additional E484K mutation (Collier et al., 2021; Wang et al., 2021b).
 98 These studies highlight the importance of an assay that can measure the
 99 humoral response to S variants in developing effective therapeutic antibodies
 100 and vaccines for COVID-19 (Burki, 2021; Priesemann et al., 2021).

101 To address this urgent need, we developed a protein microarray for the
 102 high throughput, multiplexed detection of NAbs to SARS-CoV-2 S variants.
 103 This multiplexed Spike-ACE2 Inhibitor Screening (mSAIS) assay is simple to
 104 use, able to detect NAbs to numerous S variants simultaneously, requires
 105 minimal sample volume (i.e., 20 μ L serum), and can be performed with
 106 common laboratory equipment. It could also be used with other potential
 107 neutralizing molecules (e.g., small molecules). To demonstrate the potential of
 108 the mSAIS assay, we assessed the neutralization potential of purified anti-S
 109 antibodies and serum from convalescent COVID-19 patients and vaccinees
 110 across 72 S variants. The sensitivity and resistance of the various S protein

111 mutations to the NAbS were determined, and new escape mutations that are
112 not targeted by vaccine-induced antibodies were identified. The neutralization
113 capacity of high and low titer NAb titer samples was also compared. Our
114 results were validated using a peptide-based microarray and SARS-CoV-2
115 pseudovirus neutralization assay.

116

117 **Results**

118 **Development of the mSAIS assay.**

119 The mSAIS assay enables the simultaneous screening of various potential
120 neutralizing molecules across numerous SARS-CoV-2 S variants within 2
121 hours ([Figure 1A](#)). Here, 72 S protein variants with a polyhistidine tag at the
122 C-terminus were expressed in the human embryonic kidney 293 (HEK293) cell
123 line ([Figure S1](#)), purified, and printed onto a chemically-modified glass slide as
124 previously described (Wang et al., 2020; Zhang et al., 2020b). The printed S
125 protein variants were selected from the COVID-19 virus mutation tracker
126 database ([Figure S2](#)) and literature, and included 2 variants with mutations in
127 the S protein's subunit 1 (S1) and subunit 2 (S2) domains, 7 variants with
128 mutations in S1, and 63 variants with mutations in the RBD (Alam et al., 2021).
129 Prevalent SARS-CoV-2 strains, such as the D614G, B.1.1.7, and B.1.351
130 strains, were among the variants printed. In addition, two negative controls and
131 one positive control (SARS-CoV-2 wild-type RBD) were printed on the array
132 ([Figure S3](#)). The negative controls included on the array were the

133 SARS-CoV-2 Nucleocapsid (N) protein and the RBD of the Middle East
134 respiratory syndrome coronavirus 2 (MERS-CoV-2). Following printing, the
135 sample (e.g., NAb) and a Cy5-labeled extracellular domain of ACE2 were
136 sequentially incubated on the array with alternated wash steps to remove
137 unbound sample and ACE2. Thus, S-ACE2 complex formation resulted in
138 fluorescence whereas neutralizing samples decreased fluorescence.

139 Before using the mSAIS assay to screen samples, the reproducibility of the
140 array and the binding of the S variants with ACE2 in the presence and absence
141 of NABs were evaluated. The results show that the intra- and inter-array r
142 correlations for each step of the assay were 0.99 and 0.98, respectively
143 (Figure S4, Figure 1B and 1C). Furthermore, the neutralizing capacity of 13
144 serum samples from vaccinees determined by the mSAIS assay was
145 compared to the data obtained using the live SARS-CoV-2. The r correlation
146 between the two approaches was 0.82 (Figure S5), demonstrating that the
147 mSAIS assay has high reproducibility and is a feasible approach for screening
148 potential neutralizing molecules. It is also important to note that working with
149 live SARS-CoV-2 requires biosafety level 3 (BSL3) facilities whereas the
150 mSAIS assay can be performed safely at BSL1 or BSL2 depending on the
151 nature of the tested samples.

152

153 **Characterizing ACE2 interactions with Spike variants with the mSAIS**
154 **assay**

155 By testing different amounts of purified antibodies or serum, the half maximal
156 inhibitory concentration (IC₅₀) or effective concentration (EC₅₀) can be
157 determined, respectively, and the results visualized via fluorescence. When
158 the concentration of ACE2 applied to the assay was low (≤ 2.5 $\mu\text{g/mL}$), the
159 fluorescent signal across the different S variants varied, thus indicating that the
160 binding affinities of ACE2 to the S variants are not the same (Figure 2A).
161 Indeed, the calculation of the EC₅₀ for the S variants with mutations between
162 residues 234 - 614 shows that the binding affinity (EC₅₀) ranges from 0.65 to
163 17.25 $\mu\text{g/mL}$. ACE2 had the lowest binding affinity to two S variants, F465E
164 and N487R, with an EC₅₀ of 16.16 and 17.25 $\mu\text{g/mL}$, respectively (Figure 2B).

165 The EC₅₀ ratios between the wild-type and variant S proteins were
166 calculated and log₂ transformed (Figure 2C). Using a 2-fold minimum as the
167 selection criteria, 10 mutations that weaken the S-ACE2 interaction were
168 identified, including A372T, F377L, G446V, F456E, G485S, F486S, N487R,
169 F490L, P499R and Y505C (Figure 2C and 2D). Notably, the S variant D614G
170 did not appear to affect ACE2 binding, which agrees with a previous study
171 using surface plasmon resonance (Zhang et al., 2020a).

172 Interestingly, 8/10 (80%) mutations that decreased the ability of the S
173 protein to bind ACE2 (G446V, F456E, G485S, F486S, N487R, F490L, P499R,
174 Y505C) are located at the RBD-ACE2 interaction interface (Figure 2E).
175 Moreover, F456E and N487R had the weakest ACE2 binding affinities. These
176 results further support the importance of the RBD domain in antibody

177 neutralization (Barnes et al., 2020; Dai and Gao, 2021; Tan et al., 2020).

178

179 **Heterogeneous reaction of antibodies to Spike variants**

180 Three antibodies that bind to the S protein's RBD (Figure S6) were tested with
181 the mSAIS assay, including a mouse monoclonal antibody #73, a rabbit
182 polyclonal antibody #21, and a rabbit monoclonal antibody #53 (Figure 3). The
183 IC₅₀ of antibodies #21 and #53 to the S variants range from 42.04 – 10,000
184 ng/mL and 0.00063 – 10,000 ng/mL, respectively (Figure 3B and 3C). However,
185 antibody #73 did not inhibit the RBD-ACE2 interaction (Figure 3A), indicating
186 that not all anti-RBD antibodies have neutralizing activity.

187 Antibody #21 was unable to neutralize the formation of the S-ACE2
188 complex for 8 “resistant” S variants: R408I, HV69-70 deletion/N501Y/D614G
189 (B.1.1.7 strain), G446V, F456E, N487R, F490L, Y505C, and
190 K417N/E484K/N501Y (B.1.351 strain) (Figure 3B). Two other studies also
191 observed similar results for the B.1.351 strain (Li et al., 2021; Wang et al.,
192 2021a). Using a two-fold difference in signal compared to the wild-type S
193 protein as the criteria, 33 variants showed resistance to neutralization with
194 antibody #21 (Figure 3D). Seventeen of the 33 (51.5%) mutations are located
195 between residues 437 and 508, which is the region of the RBD that physically
196 interacts with ACE2 (Singh et al., 2021) (Figure 3D and 3F, Figure S7A). Four
197 of the ten (40%) sensitive mutations are also located within the RBD interface
198 (Figure 3D and 3F, Figure S7A).

Antibody #53 had 13 escape mutations of varying resistance, with 5 mutations (F456E, F486S, N487R, N501Y, Y505C) showing complete resistance to neutralizing activity (Figure 3C and 3E). Seven (53.85%) mutations are located within the interface of the RBD-ACE2 interaction (Figure 3E and 3G, Figure S7B). Interestingly, six (46.15%) sensitive mutations are not located within the RBD-ACE2 interface (Figure 3E and 3G, Figure S7B), which indicates that binding to non-RBD binding epitopes can also have neutralization effects (Li et al., 2020; Prevost and Finzi, 2021).

Heterogeneous reaction of serological NAbS to S variants in convalescent COVID-19 patients

We next screened the serum from 25 COVID-19 patients who had recovered from SARS-CoV-2 infection. Using hierarchical cluster analysis, the convalescent patients clustered into three groups based on their NAb titers: high, low, and mixed (Figure 4A and 4B). After determining the percentage of escape mutations under three different EC50 thresholds (10, 30, 50), it was observed that the number of escape mutations were fewer for the high-titer NAb group than the low-titer NAb group (Figure 4C).

Next, the NAbS to wild-type and mutant S proteins were compared (Figure 4D). The D614G variant did not lead to a change of NAbS to S1 and S1+S2 proteins (Figure 4E, Figure S8). Using statistical analysis, the number of NAbS to eight mutated proteins was significantly decreased, including 4 known

221 escape mutations [K417N, G446V, F490L, K417N/E484K/N501Y (B.1.351
222 strain)] and 4 newly identified escape mutations (A372S, F456E, N487R,
223 Y505C) ([Figure 4F](#) and [4G](#)) (Chen et al., 2021; Li et al., 2021; Li et al., 2020;
224 Zhou et al., 2021). Notably, structural analyses show that 5 escape mutations
225 (K417N/E484K/N501Y, G446V, F456E, N487R, F490L) are located within the
226 interface of RBD-ACE2 interaction, thus indicating that this RBD subdomain is
227 important in neutralizing SARS-CoV-2 infection (Wang et al., 2020). All these
228 results demonstrate the heterogeneous reactivity of NAbS produced by
229 COVID-19 patients across S variants.

230

231 **Heterogeneous reactivity of NAbS produced by vaccinees to S variants**

232 The mSAIS assay was next used to measure the neutralizing effect of
233 antibodies produced by 30 vaccinees who received the inactivated vaccine in
234 China (Wu et al., 2021). NAbS were generated to the majority of S variants
235 ([Figure 5A](#)). Using hierarchical cluster analysis, the vaccinees consistently
236 clustered into two groups based on the level of their NAb titer: low and high
237 ([Figure 5A](#) and [5B](#)). Using three EC50 thresholds (10, 20, 30), high-titer NAb
238 group had a lower number of escape mutations compared to low-titer NAb
239 group ([Figure 5C](#)).

240 Next, the NAb titers of vaccinees across all S variants were ascertained
241 ([Figure 5D](#)). Like the convalescent COVID-19 patients, the D614G variant did
242 not alter the neutralizing effect of the NAbS compared to wild-type S1+S2, S2,

243 and RBD (Figure 5E, Figure S9). Using statistical analysis, four escape
244 mutations were identified, including 2 known (N501Y, K417N/E484K/N501Y)
245 and 2 new (K378N, P499R) mutations (Figure 5F and 5G) (Chen et al., 2021).

246 To validate the results obtained with the mSAIS assay, we analyzed the
247 NAbS with a SARS-CoV-2 pseudovirus neutralization assay displaying
248 wild-type and mutant S (wild-type, D614G, B.1.1.7, B.1.351, P.1). The results
249 for the D614G, B.1.1.7, B.1.351 variants aligned with the data obtained with
250 the mSAIS assay (Figure 5H). The vaccinees also separated into high- and
251 low-titer NAb groups (Figure 5I), further supporting the data obtained with the
252 mSAIS assay (Figure 5C).

253

254 **High titer of NAbS contain anti-Spike antibodies with diverse binding** 255 **epitopes**

256 Two recent studies with rhesus macaques have shown that a high titer of NAbS
257 produced in response to vaccination (DNA-based or adenovirus serotype 26
258 (Ad26) vector-based) provided good protection against infection when
259 challenged with SARS-CoV-2 (Mercado et al., 2020; Yu et al., 2020). In
260 another study, NAb titers were significantly higher in vaccinees who had
261 COVID-19 previously than vaccinees who never had COVID-19. Moreover, the
262 vaccinees who had been infected with SARS-CoV-2 possessed NAbS that
263 were able to neutralize all prevalent S variants (Stamatatos et al., 2021).

264 In order to provide insight into how well the high-titer NAb samples could
265 protect against SARS-CoV-2 variants, we analyzed the differential expression
266 of anti-S antibodies in the vaccinees. The level of antibodies that target the S
267 protein's S1, S2 extracellular domain (ECD), and RBD is higher in the high-titer
268 NAb group than the low-titer NAb group. Of these three antibodies, the
269 differing level of anti-RBD antibodies across the two groups was the most
270 pronounced ([Figure 6A](#)).

271 Next, we performed epitope mapping of the vaccinees' serological anti-S
272 antibodies using a tiled peptide microarray representing the full-length S
273 protein as previously described (Liang et al., 2021; Wang et al., 2020). Indeed,
274 the results indicate that the high-titer NAb group bound to more diverse
275 epitopes than the low-titer NAb group ([Figure 6B](#)). The number of
276 immunogenic peptides within the S1, S2ECD, and RBD is also consistently
277 higher in the high-titer NAb group ([Figure 6C](#)).

278 To further validate our findings, sera from the 104 vaccinees were
279 analyzed using a SARS-CoV-2 pseudovirus neutralization assay. Prior to data
280 analysis, all vaccinees were separated into three groups according to their
281 NAb titers (<10, 10-50, >50). Notably, the results show that the concentration
282 of anti-S antibodies is proportional to the concentration of NABs. However,
283 there was no difference in the levels of anti-S1 antibodies that target the
284 N-terminus or C-terminus across the vaccinees. The levels of anti-S2 ECD
285 antibodies were significantly different only between NAb titers of <10 and >50

(Figure 7A). These results demonstrate that the antibodies produced in response to vaccination of inactivated vaccine primarily target the RBD (Figure 6A and 7A).

The peptide microarray was also employed to examine serological NAb with a larger vaccinated cohort (n=104). The data confirm that the anti-S antibodies in the high-titer NAb group bind to more peptides representing the S1, S1 N-terminal domain, RBD, and S2 ECD of the S protein than the low-titer NAb group (Figure 7B, 7C). These data indicate that high NAb titers contain anti-S antibodies with increased binding diversity.

Discussion

The SARS-CoV-2 virus has mutated over time, resulting in circulating viral strains with altered transmission efficiencies, mortality rates, and S variants that can escape from the neutralizing effect of antibodies (Alam et al., 2021) (Davies et al., 2021; Hou et al., 2020b; Prevost and Finzi, 2021). Therefore, significant effort has been devoted to improve the diagnosis, prevention, and treatment of COVID-19 patients infected with SARS-CoV-2 variants (Abdool Karim and de Oliveira, 2021).

In this work, we developed an mSAIS assay that enables the detection of NAb to numerous S variants simultaneously and rapidly. It has numerous advantages compared to the enzyme-linked immunosorbent assay (ELISA) and pseudovirus neutralization assays (Li et al., 2021; Tan et al., 2020;

308 Weisblum et al., 2020). First, our flexible platform can be easily adapted to
309 include new S variants as they emerge. Second, only a laser scanner capable
310 of detecting Cy5 is required to perform the mSAIS assay. Third, the
311 multiplexed nature of the platform significantly reduces the sample volume,
312 reagents, time, and cost to obtain data compared to single-plexed assays (Xu
313 et al., 2020). For example, only 20 μ L of serum was needed to screen for NABs
314 against 72 S variants in this study. In comparison, the volume requirements for
315 ELISA or the pseudovirus neutralization assay would be 1,440 (72 $\times$) or 3,240
316 (162 $\times$) μ L, respectively.

317 Using the mSAIS assay, we compared purified mouse and rabbit
318 antibodies. Of the three antibodies tested, antibody #53 was able to inhibit the
319 S-ACE2 interaction across the most S variants, thus it is a superior candidate
320 for COVID-19 therapy. The comprehensive mapping of antibodies to different
321 S variants would be valuable in understanding the sensitivity of mutations to
322 antibody neutralization, and help develop antibody cocktails for COVID-19
323 therapy (Li et al., 2021; Li et al., 2020; Prevost and Finzi, 2021; Starr et al.,
324 2021).

325 Using serum from convalescent COVID-19 patients and vaccinees with
326 the mSAIS assay, we identified 4 and 2 new resistant mutations, respectively,
327 that escape NAB recognition (Figures 4 and 5). We also show that there are
328 fewer escape mutations in high NAB titers than low titers, and this was
329 observed in both convalescent COVID-19 patients and vaccinees (Figures 4C

330 and 5C). Using a large cohort of 104 vaccinees with multiple assays (i.e.,
331 mSAIS assay, peptide array, pseudovirus neutralization assay), we further
332 demonstrate that high titer NAb contain anti-S antibodies that target more
333 diverse binding epitopes, thus leading to more neutralizing capacity across a
334 breadth of S variants (Figure 6 and 7). The production of heterogenous
335 antibodies could be due to the somatic mutations that occur during antibody
336 maturation (Muecksch et al., 2021). Finally, our data suggest that an effective
337 COVID-19 vaccination strategy to defend against the mutating SARS-CoV-2 is
338 to elicit the immune response to produce high-titer NAb that contain a large
339 diversity of anti-S antibodies (Stamatatos et al., 2021; Starr. et al., 2021).
340 However, the association between NAb titer and its ability to protect against
341 SARS-CoV-2 infection in humans is unclear (Jin et al., 2021).

342 There were several limitations in this study. First, the mSAIS assay is *in*
343 *vitro*, which might not accurately reflect results *in vivo*. Second, some
344 conformational and glycosylation epitopes might not be detected using the
345 peptide microarray that employed chemically-synthesized peptides (Wang et
346 al., 2020). Finally, the number of serum samples from convalescent COVID-19
347 patients and vaccinees were limited. The results obtained in this study should
348 be validated in a large different cohort in the future.

349

350 Conclusion

351 Altogether, we developed a high-throughput microarray-based mSAIS assay,

which enables the multiplexed and rapid screening of NABs to SARS-CoV-2 S variants. Using the mSAIS assay, we confirmed the neutralization capabilities of NABs to known mutations, identified a number of new mutations that are resistant to the NABs, and showed that there were fewer escape mutations with high NAB titers than low NAB titers in both convalescent COVID-19 patients and vaccinees. The data demonstrate the great potential of our proteomics platform in mapping the ability of NABs to block the interaction between SARS-CoV-2 S variants and ACE2 interactions. Although we tested purified antibodies and serum in this study, the mSAIS assay could be used with other sample types as well. Data gleaned from the mSAIS will help develop more effective vaccines and therapeutic antibodies to fight against COVID-19.

364

365 **References**

- 366 Abdool Karim, S.S., and de Oliveira, T. (2021). New SARS-CoV-2 Variants - Clinical, Public Health,
367 and Vaccine Implications. *N Engl J Med* 384,1866-1868.
- 368 Alam, I., Radovanovic, A., Incitti, R., Kamau, A.A., Alarawi, M., Azhar, E.I., and Gojobori, T. (2021).
369 CovMT: an interactive SARS-CoV-2 mutation tracker, with a focus on critical variants. *Lancet Infect Dis*
370 21,602.
- 371 Aschwanden, C. (2021). Five reasons why COVID herd immunity is probably impossible. *Nature* 591,
372 520-522.
- 373 Barnes, C.O., Jette, C.A., Abernathy, M.E., Dam, K.A., Esswein, S.R., Gristick, H.B., Malyutin, A.G., Sharaf,
374 N.G., Huey-Tubman, K.E., Lee, Y.E., *et al.* (2020). SARS-CoV-2 neutralizing antibody structures inform
375 therapeutic strategies. *Nature* 588, 682-687.
- 376 Burki, T. (2021). Understanding variants of SARS-CoV-2. *Lancet* 397, 462.
- 377 Chen, R.E., Zhang, X., Case, J.B., Winkler, E.S., Liu, Y., VanBlargan, L.A., Liu, J., Errico, J.M., Xie, X.,
378 Suryadevara, N., *et al.* (2021). Resistance of SARS-CoV-2 variants to neutralization by monoclonal and
379 serum-derived polyclonal antibodies. *Nat Med* 27,717-726.
- 380 Collier, D.A., De Marco, A., Ferreira, I., Meng, B., Datir, R., Walls, A.C., Kemp, S.S., Bassi, J., Pinto, D.,
381 Fregni, C.S., *et al.* (2021). Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.

382 Nature 593,136-141.

383 Dai, L., and Gao, G.F. (2021). Viral targets for vaccines against COVID-19. *Nat Rev Immunol* 21, 73-82.

384 Davies, N.G., Jarvis, C.I., Group, C.C.-W., Edmunds, W.J., Jewell, N.P., Diaz-Ordaz, K., and Keogh, R.H.

385 (2021). Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. *Nature*

386 593,270-274.

387 Del Rio, C., and Malani, P. (2021). COVID-19 in 2021-Continuing Uncertainty. *JAMA* 325,1389-1390.

388 Dong, E., Du, H., and Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real

389 time. *Lancet Infect Dis* 20, 533-534.

390 Galloway, S.E., Paul, P., MacCannell, D.R., Johansson, M.A., Brooks, J.T., MacNeil, A., Slayton, R.B., Tong,

391 S., Silk, B.J., Armstrong, G.L., *et al.* (2021). Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States,

392 December 29, 2020-January 12, 2021. *MMWR Morb Mortal Wkly Rep* 70, 95-99.

393 Garcia-Beltran, W.F., Lam, E.C., St Denis, K., Nitido, A.D., Garcia, Z.H., Hauser, B.M., Feldman, J.,

394 Pavlovic, M.N., Gregory, D.J., Poznansky, M.C., *et al.* (2021). Multiple SARS-CoV-2 variants escape

395 neutralization by vaccine-induced humoral immunity. *Cell* 184,2372-2383.e9.

396 Hou, X., Zhang, X., Wu, X., Lu, M., Wang, D., Xu, M., Wang, H., Liang, T., Dai, J., Duan, H., *et al.* (2020a).

397 Serum Protein Profiling Reveals a Landscape of Inflammation and Immune Signaling in Early-stage

398 COVID-19 Infection. *Mol Cell Proteomics* 19, 1749-1759.

399 Hou, Y.J., Chiba, S., Halfmann, P., Ehre, C., Kuroda, M., Dinno, K.H., 3rd, Leist, S.R., Schafer, A.,

400 Nakajima, N., Takahashi, K., *et al.* (2020b). SARS-CoV-2 D614G variant exhibits efficient replication ex

401 vivo and transmission in vivo. *Science* 370, 1464-1468.

402 Jin, P., Li, J., Pan, H., Wu, Y., and Zhu, F. (2021). Immunological surrogate endpoints of COVID-2019

403 vaccines: the evidence we have versus the evidence we need. *Signal Transduct Target Ther* 6, 48.

404 Kemp, S.A., Collier, D.A., Datir, R.P., Ferreira, I., Gayed, S., Jahun, A., Hosmillo, M., Rees-Spear, C.,

405 Mlcochova, P., Lumb, I.U., *et al.* (2021). SARS-CoV-2 evolution during treatment of chronic infection.

406 *Nature* 592,277-282.

407 Korber, B., Fischer, W.M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi,

408 E.E., Bhattacharya, T., Foley, B., *et al.* (2020). Tracking Changes in SARS-CoV-2 Spike: Evidence that

409 D614G Increases Infectivity of the COVID-19 Virus. *Cell* 182, 812-827 e819.

410 Li, Q., Nie, J., Wu, J., Zhang, L., Ding, R., Wang, H., Zhang, Y., Li, T., Liu, S., Zhang, M., *et al.* (2021).

411 SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape. *Cell*

412 184,2362-2371.e9.

413 Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., *et al.* (2020). The

414 Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. *Cell* 182, 1284-1294

415 e1289.

416 Liang, T., Cheng, M., Teng, F., Wang, H., Deng, Y., Zhang, J., Qin, C., Guo, S., Zhao, H., and Yu, X. (2021).

417 Proteome-wide epitope mapping identifies a resource of antibodies for SARS-CoV-2 detection and

418 neutralization. *Signal Transduct Target Ther* 6, 166.

419 Liu, Y., Liu, J., Xia, H., Zhang, X., Fontes-Garfias, C.R., Swanson, K.A., Cai, H., Sarkar, R., Chen, W., Cutler,

420 M., *et al.* (2021). Neutralizing Activity of BNT162b2-Elicited Serum. *N Engl J Med* 384,1466-1468.

421 Madhi, S.A., Baillie, V., Cutland, C.L., Voysey, M., Koen, A.L., Fairlie, L., Padayachee, S.D., Dheda, K.,

422 Barnabas, S.L., Bhorat, Q.E., *et al.* (2021). Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against

423 the B.1.351 Variant. *N Engl J Med*, NEJMoa2102214.

424 Mercado, N.B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K.,

425 Tostanoski, L.H., *et al.* (2020). Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus

macaques. *Nature* 586, 583-588.

Muecksch, F., Weisblum, Y., Barnes, C.O., Schmidt, F., Schaefer-Babajew, D., Lorenzi, J.C.C., Flyak, A.I., DeLaitch, A.T., Huey-Tubman, K.E., Hou, S., *et al.* (2021). Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies. *bioRxiv*.

Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., *et al.* (2020). Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay. *Nat Protoc* 15, 3699-3715.

Prevost, J., and Finzi, A. (2021). The great escape? SARS-CoV-2 variants evading neutralizing responses. *Cell Host Microbe* 29, 322-324.

Priesemann, V., Balling, R., Brinkmann, M.M., Ciesek, S., Cypionka, T., Eckerle, I., Giordano, G., Hanson, C., Hel, Z., Hotulainen, P., *et al.* (2021). An action plan for pan-European defence against new SARS-CoV-2 variants. *Lancet* 397, 469-470.

Singh, A., Steinkellner, G., Kochl, K., Gruber, K., and Gruber, C.C. (2021). Serine 477 plays a crucial role in the interaction of the SARS-CoV-2 spike protein with the human receptor ACE2. *Sci Rep* 11, 4320.

Stamatatos, L., Czartoski, J., Wan, Y.H., Homad, L.J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M.F., MacCamy, A.J., *et al.* (2021). mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. *Science*, eabg9175.

Starr, T.N., Greaney, A.J., Dingens, A.S., and Bloom, J.D. (2021). Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. *Cell Rep Med* 2,100255.

Starr, T., Czudnochowski, N., Zatta, F., Park, Y., Veasler, D., Corti, D., Bloom, J., and Snell, G. (2021). Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape. *bioRxiv*.

Tan, C.W., Chia, W.N., Qin, X., Liu, P., Chen, M.L., Tiu, C., Hu, Z., Chen, V.C., Young, B.E., Sia, W.R., *et al.* (2020). A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. *Nat Biotechnol* 38, 1073-1078.

Wang, H., Wu, X., Zhang, X., Hou, X., Liang, T., Wang, D., Teng, F., Dai, J., Duan, H., Guo, S., *et al.* (2020). SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution. *ACS Cent Sci* 6, 2238-2249.

Wang, P., Nair, M.S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P.D., *et al.* (2021a). Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. *Nature* 593,130-135.

Wang, P., Wang, M., Yu, J., Cerutti, G., Nair, M.S., Huang, Y., Kwong, P.D., Shapiro, L., and Ho, D.D. (2021b). Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. *bioRxiv*.

Wang, H., Hou, X., Zhang, X., Wu, X., Liang, T., Wang, D., Teng, F., Dai, J., Duan, H., Guo, S., *et al.* (2020). SARS-CoV-2 proteome microarray for mapping COVID-19 antibody interactions at amino acid resolution. *ACS Cent Sci* 6,2238-2249.

Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J.C., Muecksch, F., Rutkowska, M., Hoffmann, H.H., Michailidis, E., *et al.* (2020). Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. *Elife* 9,e61312.

Wibmer, C.K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Oosthuysen, B., Lambson, B.E., de Oliveira, T., Vermeulen, M., van der Berg, K., *et al.* (2021). SARS-CoV-2 501YV2 escapes neutralization by South African COVID-19 donor plasma. *Nat Med* 27,622-625.

Wu, Z., Hu, Y., Xu, M., Chen, Z., Yang, W., Jiang, Z., Li, M., Jin, H., Cui, G., Chen, P., *et al.* (2021). Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults

aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis*, S1473-3099(20)30987-7.

Xu, M., Deng, J., Xu, K., Zhu, T., Han, L., Yan, Y., Yao, D., Deng, H., Wang, D., Sun, Y., *et al.* (2019). In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine. *Theranostics* 9, 2475-2488.

Xu, M., Wang, D., Wang, H., Zhang, X., Liang, T., Zhang, K., Zhang, J., Xu, D., and Yu, X. (2020). COVID-19 diagnostic testing: Technology perspective. *Clin Transl Med*, e158.

Yu, J., Tostanoski, L.H., Peter, L., Mercado, N.B., McMahan, K., Mahrokhian, S.H., Nkolola, J.P., Liu, J., Li, Z., Chandrashekar, A., *et al.* (2020). DNA vaccine protection against SARS-CoV-2 in rhesus macaques. *Science* 369, 806-811.

Zhang, L., Jackson, C.B., Mou, H., Ojha, A., Peng, H., Quinlan, B.D., Rangarajan, E.S., Pan, A., Vanderheiden, A., Suthar, M.S., *et al.* (2020a). SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. *Nat Commun* 11, 6013.

Zhang, N.N., Li, X.F., Deng, Y.Q., Zhao, H., Huang, Y.J., Yang, G., Huang, W.J., Gao, P., Zhou, C., Zhang, R.R., *et al.* (2020b). A Thermostable mRNA Vaccine against COVID-19. *Cell* 182, 1271-1283 e1216.

Zhou, D., Dejnirattisai, W., Supasa, P., Liu, C., Mentzer, A.J., Ginn, H.M., Zhao, Y., Duyvesteyn, H.M.E., Tuekprakhon, A., Nutalai, R., *et al.* (2021). Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell* 184, 2348-2361.

Contributions

J.Z. and L.X. provided the purified spike variant proteins. M. Z., S. Y., C. H., Y. H., and Y. W. provided the clinical samples. X. Z., H. W., J. Z., J. R., H. B., and X. Y. executed microarray experiments. X. Z., T. L., H. P., S. L., C.W., and X.Y. executed the bioinformatics and statistical analyses. J.V. executed the pseudovirus based neutralization assay. H. Z., M. L., X. H., and B. K. executed the authentic virus-based neutralization assay. X.Y., Y. W., and B. K. conceived the idea, designed experiments, analyzed the data, and wrote the manuscript.

Acknowledgement

This work was supported by the National Natural Science Foundation of China (31870823), National Key R&D Program of China (2020YFE0202200), State

501 Key Laboratory of Proteomics (SKLP-C202001, SKLP-O201904,
502 SKLP-O201703, SKLP-O202007), the National Program on Key Basic
503 Research Project (2018YFA0507503, 2017YFC0906703, 2018ZX09733003)
504 and the Beijing Municipal Education Commission, Beijing Municipal Natural
505 Science Foundation (M21003) and Beijing Municipal Science & Technology
506 Commission (Z201100001020001; Z201100005420022). We thank Dr.
507 Brianne Petritis for her critical review and editing of this manuscript.

508

509 **Competing interests**

510 None declared.

511

512 **Supplemental information**

513 The supplemental information includes 3 supplementary tables and 9
514 supplementary figures.

515

516 **Figures and legends**

517 **Figure 1. Development of the mSAIS assay.** (A) A schematic illustration of
518 the microarray-based mSAIS assay and potential biomedical applications; (B,
519 C) Intra- and inter-array reproducibility of the mSAIS assay in the absence and
520 presence of neutralizing antibodies, respectively.

521

522 **Figure 2. SARS-CoV-2 S-ACE2 interaction mapping across different S**

523 **variants using the mSAIS assay.** (A) Detection of different concentrations of
524 ACE2 binding to S variants immobilized on the array. (B) Distribution of
525 S-ACE2 binding affinities (EC50) across different SARS-CoV-2 S variants. (C)
526 Fold changes of binding affinity between the wild-type and mutated S proteins.
527 The x-axis represents the S variants and the y-axis represents the log2
528 transformed IC50 ratio between the wild-type and mutated S proteins. (D) are
529 the dynamic curves representing S variants that bind to ACE2 with significantly
530 decreased binding affinity compared to the wild-type S protein. (E) Structural
531 analysis of escape mutations on the RBD (gray color) that interacts with ACE2
532 (green color). RBD mutations (PDB ID: 6M0J) are labelled in red.

533

534 **Figure 3. Heterogeneous responses of purified antibodies to**
535 **SARS-CoV-2 mutations.** (A-C) Distribution of neutralization activity (IC50) of
536 purified antibodies #73, #21 and #53 to the S variants, respectively. The x-axis
537 represents the S variants and the y-axis represents the neutralization activity
538 (IC50) of the monoclonal antibody to each spike variant. (D, E) Fold changes
539 of the neutralization activity (IC50) of antibodies #21 and #53 between the
540 wild-type and mutant S proteins, respectively. The x-axis represents the S
541 variants and the y-axis represents the log2 transformed IC50 ratio between the
542 wild-type and mutated S proteins. (F, G) Structural analysis of the mutations
543 that decrease and increase the neutralization activity of antibodies #21 and
544 #53, respectively.

545

546 **Figure 4. Heterogeneous responses of serological NAbS to SARS-CoV-2**

547 **S mutations in convalescent COVID-19 patients.** (A) Hierarchical cluster

548 analysis of NAbS to S variants in convalescent COVID-19 patients. The

549 rainbow color from white to red correspond to the NAb titer from low to high,

550 respectively. (B) EC50 comparison of convalescent COVID-19 patients with

551 high and low NAb titers. (C) Comparison of escape mutations between

552 convalescent COVID-19 patients with high and low NAb titers with EC50

553 thresholds set at 10, 30 and 50, respectively. (D) Distribution of serological

554 NAbS to different SARS-CoV-2 S variants in convalescent COVID-19 patients.

555 (E) Comparison of NAbS between the wild-type and D614G S proteins. (F)

556 Comparison of NAbS between the wild-type S protein and S variants with

557 known escape mutations. (G) Comparison of NAbS between the wild-type S

558 protein and S variants with newly identified escape mutations. Significant

559 escape mutations were identified using an unpaired t test with a p value of

560 0.05.

561

562 **Figure 5. Heterogeneous responses of serological NAbS to the**

563 **SARS-CoV-2 S mutations in vaccinated individuals.** (A) Hierarchical cluster

564 analysis of NAbS to S variants in vaccinees. The rainbow color from white to

565 red correspond the NAb titers from low to high, respectively. (B) EC50

566 comparison of vaccinees with high and low NAb titers. (C) Comparison of

567 escape mutations between vaccinees with high and low NAb titers with EC50
568 thresholds set at 10, 20 and 30, respectively. (D) Distribution of serological
569 NAbs to different SARS-CoV-2 S variants in vaccinees. (E) Comparison of
570 NAbs between the wild-type and D614G S proteins. (F) Comparison of NAbs
571 between the wild-type S protein and S variants with known escape mutations.
572 (G) Comparison of NAbs between the wild-type S protein and S variants with
573 newly-identified escape mutations. Significant escape mutations were
574 identified using an unpaired t test with a p-value of 0.05. (H) Detection of
575 serological NAbs to prevalent SARS-CoV-2 variants in the vaccinees using the
576 pseudovirus neutralization assay. (I) Hierarchical cluster analysis of the NAbs
577 to prevalent SARS-CoV-2 variants in vaccinees. The rainbow color from white
578 to red correspond the NAb titers from low to high, respectively.

579

580 **Figure 6. The NAb titer is associated with the diversity of anti-S**
581 **antibodies in the serum of vaccinees.** (A) A comparison of levels of
582 antibodies that target the S1, RBD and S2 ECD. (B) Identification of
583 vaccine-induced humoral immune responses to the S protein. (C) Association
584 between the number of immunogenic peptides and NAb titers. A p-value (p) <
585 0.05 by Mann-Whitney test was considered to be significant. NTD = N-terminal
586 domain

587

588 **Figure 7. Validation of anti-S antibody diversity in 104 vaccinees.** (A) A

589 comparison of levels of antibodies that target the S proteins and its domains.

590 (B) Landscape of vaccine-induced humoral immune responses to the S protein.

591 (C) Association between the number of immunogenic peptides and NAb titers.

592 A p-value (p) < 0.05 by Mann-Whitney test was considered to be significant.

593 CTD = C-terminal domain; NTD = N-terminal domain. The NAb titers (ND50)

594 was measured using pseudovirus neutralization assay.

595

596 **Materials and methods**

597 **Collection of patient samples**

598 Clinical specimens were obtained from the Department of Clinical Laboratory

599 in Beijing Ditan Hospital, Capital Medical University (Beijing, China). Whole

600 blood was collected in a vacutainer tube, and centrifuged at 4,000×g at room

601 temperature (RT) for 10 minutes to separate serum. Serum was then

602 transferred to a clean tube and stored at -80°C until use. For safety purposes,

603 serum collected from convalescent COVID-19 patients was inactivated at 56°C

604 for 30 minutes prior to any further sample processing. Notably, serum from

605 COVID-19 vaccinated individuals was obtained from healthy hospital staff 4

606 weeks after receiving the second vaccine dose, and convalescent samples

607 were collected from COVID-19 patients 2 to 4 weeks post discharge. Our

608 research was approved by the Ethics Committee of Beijing Ditan Hospital (No.

609 2021-010-01), and exemption of informed consent was obtained prior to sera

610 collection.

611

612 **Expression and purification of recombinant proteins for use on the**
613 **mSAIS assay**

614 The DNA sequence encoding the SARS-CoV-2 Spike protein (S1+S2 ECD)
615 (YP_009724390.1) (Val 16-Pro1213), S1 Subunit (YP_009724390.1)
616 (Val16-Arg685), RBD (YP_009724390.1) (Arg319-Phe541) or variants were
617 expressed with a polyhistidine tag at the C-terminus. The generation of
618 variants using site-directed mutagenesis was performed as previously
619 described (Li et al., 2020). In addition, two negative controls [SARS-CoV-2
620 Nucleocapsid (N), MERS-CoV-2 Spike RBD], one positive control
621 (SARS-CoV-2 wild-type RBD), and the extracellular domain of ACE2 were
622 expressed with a polyhistidine tag at the C-terminus. The proteins were
623 expressed in HEK293 cells, followed by further purification on a Ni-NTA spin
624 column (Thermo Fisher). Protein purity was confirmed using an SDS-PAGE gel
625 stained with Coomassie blue.

626

627 **Preparation of the mSAIS microarray**

628 All purified proteins were diluted to 100 µg/mL and printed onto a
629 three-dimensional (3D)-modified slide surface (Capital Biochip Corp, Beijing,
630 China) in parallel and in duplicate using an Arrayjet microarrayer (Roslin, UK)
631 as previously described (Hou et al., 2020a; Wang et al., 2020; Xu et al., 2019).
632 The protein microarrays were stored at -20 °C until ready to use.

633

634 **Detection of NAbS using the mSAIS assay**

635 Prior to antibody detection, the protein microarrays were assembled in an
636 incubation tray and blocked with 1% (w/v) milk in 1x phosphate buffered saline,
637 pH 7.2 (PBS), with 0.2% (v/v) Tween-20 (PBST) for 10 min at room
638 temperature. After washing with PBST three times, the array was incubated
639 with serum diluted 10- to 320-fold in PBST for 30 min at room temperature.
640 After washing again, the array was then incubated for 60 min with Cy5-labeled
641 ACE2 (50 ng/mL). Finally, the array was washed with PBST and water,
642 dissembled from the tray, and dried via centrifugation for 2 min at 2,000 rpm.
643 The array was scanned with a GenePix 4300A microarray scanner (Molecular
644 Devices, Sunnyvale, CA, USA) at a 10 μ m resolution using a laser at 635 nm
645 with 100% power/ PMT Gain 900. The median fluorescent signal intensity with
646 background subtraction was extracted using GenePix Pro7 software
647 (Molecular Devices, Sunnyvale, CA, USA).

648

649 **SARS-CoV-2 pseudovirus neutralization assay**

650 The SARS-CoV-2 pseudovirus neutralization assay was performed as
651 previously described (Nie et al., 2020). Briefly, human sera were diluted using
652 3-fold serial dilutions with a starting concentration of 1:10 (two per dilution).
653 The diluted sera were added into 96-well plates in duplicate, followed by the
654 SARS-CoV-2 pseudovirus at a concentration of 1300 median tissue culture

655 infective dose (TCID₅₀/mL). The sera and pseudovirus were incubated
656 together at 37°C for 1 hour, and then monkey Vero cells were added at 2*10⁴
657 cells/100 mL cells per well. The plates were incubated at 37°C in a humidified
658 atmosphere with 5% CO₂ for 24 hours before chemiluminescence detection
659 was performed. The Reed-Muench method was used to calculate the
660 neutralization titer.

661

662 Live SARS-CoV-2 neutralization assay

663 A suspension of Vero cells suspension was prepared at a cell density of
664 2×10⁵/ml. Serum samples were diluted 4-fold in cell culture medium and
665 inactivated at 56°C for 30 minutes. The inactivated serum was serially diluted
666 2-fold with MEM medium, followed by the addition of cell culture medium
667 containing 100 times the cell culture infective dose 50% (CCID₅₀) of wild-type
668 SARS-CoV-2 virus. The mixture was placed into a 96-well plate and incubated
669 at 37°C for 2 h in CO₂ 5%, and then 2×10⁴ Vero cells were added and
670 incubated again at 37°C. The samples were microscopically examined for
671 cytopathic effect (CPE) after 7 days. The highest dilution of serum that showed
672 complete inhibition activity of SARS-CoV-2 was recorded as the neutralizing
673 antibody titer (ID₅₀). Assays were performed in duplicate with negative control
674 serum.

675 The ID₅₀ was calculated as: $\text{LogCCID}_{50} = X_m + \frac{1}{2d} - \frac{1}{d} \sum \frac{p_i}{100}$, where
676 X_m is the log₁₀ of maximum dilution of the virus, the d is the logarithm of the

dilution fold, and $\sum p_i$ is the sum of the percentage of the cytopathic effect per dilution.

679

680 **Detection of SARS-CoV-2 serum antibodies using a SARS-CoV-2** 681 **proteome peptide microarray**

682 The peptide microarray containing truncated S proteins, and tiled peptides
683 representing SARS-CoV-2 S protein was prepared as our previous work (Liang
684 et al., 2021; Wang. et al., 2020). The array was assembled in an incubation
685 tray and blocked with 5% (w/v) milk in phosphate-buffered saline (PBS)
686 containing 0.05% (v/v) Tween-20 (PBST) for 30 min at room temperature
687 before antibody detection. After aspirating the blocking solution, the 1:200
688 diluted serum was added to the array and incubated at room temperature for
689 20 min. After washing three times with PBST, the array was then incubated for
690 20 min with a Cy3 labelled donkey anti-human IgG(H+L) antibody (Jackson
691 ImmunoResearch, USA) (2 μ g/mL). Finally, the array was washed with PBST
692 and deionized water, disassembled from the tray and dried with vacuum pump.
693 The slide was scanned at 532 nm using a GenePix 4300A microarray scanner
694 (Molecular Devices, Sunnyvale, CA, USA). The median fluorescent signal
695 intensity of each spot with background subtraction was extracted using
696 GenePix Pro7 software (Molecular Devices, Sunnyvale, CA, USA).

697

698 **Data analysis**

699 The ability of the serological NAbs to inhibit the S-ACE2 interactions across
700 the different S variants was visualized as a heatmap using the MultiExperiment
701 Viewer software version 4.9 (Chu et al., 2008). Statistical analyses were
702 performed using the GraphPad Prism software 8.3 and Microsoft Excel with
703 the unpaired t test and Mann-Whitney test. A p-value (p) < 0.05 was
704 considered to be significant. * p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001.
705 The 3D structure of the SARS-CoV-2 RBD and ACE2 complex (PDB ID code:
706 6M0J) was visualized using the VMD 1.9.3, and mutations were annotated.

A**Assay Principle**

SARS-CoV-2 spike variant protein microarray

72 spike variant proteins

- K417N
- N501Y
- K417N/E484K/N501Y
-

EC50

NAbs

Applications

Spike variants that are sensitive and resistant to NAbs

NAbs generated in SARS-CoV-2 infected patients

Humoral response to COVID-19 vaccination

B

Detection of Spike-ACE2 Binding

Within an array

Between different arrays

C

Detection of Spike-ACE2 Binding with NAbs

Within an array

Between different arrays

A **B** **C**